The Trump administration has chosen not to cover popular obesity medications under Medicare's Part D, reversing a proposal from Joe Biden's administration to broaden access. Despite public support for such coverage, Trump's Centers for Medicare and Medicaid Services (CMS) did not provide details for their decision. Critics, including Health and Human Services Secretary Robert F. Kennedy Jr., have targeted these drugs due to rising popularity and expense, while proponents argue that obesity treatments could reduce long-term healthcare costs by preventing serious conditions. This decision underscores ongoing debates surrounding healthcare funding and access.
Trump's administration has decided to exclude expensive obesity treatments from Medicare coverage, emphasizing a reversal from prior proposals aimed at expanding access for these medications.
Despite public support for Medicare coverage of obesity drugs, the decision highlights ongoing tensions between cost management and patient care, as seen with Trump's administration's health policies.
Collection
[
|
...
]